{"disease":{"id":"management-of-pain-severe-enough-to-require-an-opioid-analgesic","name":"Management of pain severe enough to require an opioid analgesic","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"naloxone-hydrochloride","indication_name":"Management of pain severe enough to require an opioid analgesic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"naloxone-hydrochloride","guideline_body":"FDA label","recommendation":"Reserve opioid analgesics, including Pentazocine and Naloxone Tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null},{"drug_id":"naloxone-hydrochloride","guideline_body":"FDA label","recommendation":"Reserve opioid analgesics, including Pentazocine and Naloxone Tablets, for use in patients for whom alternative treatment options are ineffective.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null},{"drug_id":"naloxone-hydrochloride","guideline_body":"FDA label","recommendation":"Reserve opioid analgesics, including Pentazocine and Naloxone Tablets, for use in patients for whom alternative treatment options are not tolerated.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null},{"drug_id":"naloxone-hydrochloride","guideline_body":"FDA label","recommendation":"Reserve opioid analgesics, including Pentazocine and Naloxone Tablets, for use in patients for whom alternative treatment options would be otherwise inadequate.","line_of_therapy":"any","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}